Caldera Therapeutics agreed to a reverse merger with Synlogic and raised a $278 million private financing to support a mid-stage inflammatory bowel disease asset. The funding is intended to back development of CLD-423, a bispecific targeting TL1A and IL-23p19, with Phase 1 testing underway and data expected by the end of 2026. The Caldera-Synlogic structure continues a pattern of investors using public reverse mergers to accelerate market access for asset-driven biotechs. Synlogic previously went public via reverse merger and has dealt with clinical setbacks, including layoff plans in 2024. Caldera’s merger cash is positioned to fund through Phase 2, while separate reporting ties the wider deal flow to China-licensed I&I programs gaining capital leverage. The transaction will be watched for whether CLD-423 can translate preclinical or early clinical promise into differentiating efficacy within established IBD treatment classes.